Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.

doi:10.1186/s12885-020-6593-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.

BMC cancer - 6 Feb 2020

Tokudome Nahomi, Koh Yasuhiro, Akamatsu Hiroaki, Fujimoto Daichi, Okamoto Isamu, Nakagawa Kazuhiko, Hida Toyoaki, Imamura Fumio, Morita Satoshi, Yamamoto Nobuyuki

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR)-sensitizing mutation, exon 19 deletion consists of several molecular variants. Influences of these variants on clinical response to EGFR tyrosine kinase inhibitors remain elusive. METHODS: West Japan Oncology Group 8114LTR is a prospective, multi-institutional biomarker study. Treatment naïve, advanced non-small-cell lung cancer patients with EGFR-sensitizing...

Topics

Adult
Afatinib
Aged
Alleles
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Exons
Female
Genetic Association Studies
Genotype
Humans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Lung Neoplasms

Male

Middle Aged

Neoplasm Staging

Protein Kinase Inhibitors

Recurrence

Sequence Deletion

Source

Open in PubMed Open full text

Identifiers

PMID: 32028909
DOI: 10.1186/s12885-020-6593-1
PMCID: PMC7006223

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.PMID 32028909Read ↗

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patientsSemantic proximity Read ↗

Patients Harboring Uncommon EGFR Exon 19 Deletion-insertion Mutations Respond Well to First-generation EGFR Inhibitors and Osimeritinib Upon Acquisition of T790MSemantic proximity Read ↗

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.Semantic proximity Read ↗

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.Semantic proximity Read ↗

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.Semantic proximity Read ↗

Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.Semantic proximity Read ↗

Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review)Semantic proximity Read ↗

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.Semantic proximity Read ↗

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21Semantic proximity Read ↗

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.Semantic proximity Read ↗

Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.